Tirzepatide denied due to quantity / dose limits by Aetna?

Aetna's specific coverage criteria for tirzepatide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Applied a Quantity Limit to Tirzepatide

Aetna's quantity-limit denial means the plan has approved tirzepatide in principle but is restricting the quantity dispensed per fill or per period — typically to align with standard dosing schedules as defined in its drug policy. This most often affects patients whose prescription was written for a quantity or supply duration that exceeds the plan's stated limit, or who are requesting a fill before the plan's refill-too-soon window has passed.

Quantity-limit denials are appealable when the prescribed quantity is medically justified — for example, when your prescriber has clinical reasons documented in the chart for the specific supply requested, or when the plan's standard limit does not accommodate the titration schedule described in the FDA-approved prescribing information.

## Your Appeal Rights

• ACA §2719 / ERISA §503: Federal law requires full-and-fair internal appeal rights and access to independent external review for most non-grandfathered plans.
• Internal appeal deadline: Typically 180 days from the denial notice; confirm on your Explanation of Benefits.
• External review window: Approximately four months from a final internal denial to file for independent external review.
• Expedited review: Request this in writing if a supply gap would pose an urgent health risk.

## Documentation to Gather

1. FDA prescribing information — titration schedule: The FDA-approved label for tirzepatide includes the manufacturer's recommended titration schedule. If your prescribed quantity aligns with that schedule, document the match explicitly. 2. Prescriber rationale for quantity: Your prescriber should document in the chart — and in a letter — the clinical reason for the quantity prescribed, including whether you are in a titration phase, stabilization phase, or maintenance phase, and why the requested supply is appropriate. 3. Diagnosis confirmation and treatment plan: Current chart notes confirming your diagnosis and the treatment plan tirzepatide supports, with a timeline. 4. Prior fill history: A record of prior fills that demonstrates your usage is consistent with the prescribed regimen and the FDA-approved titration schedule. 5. Insurer policy mapping: Obtain Aetna's current quantity-limit policy for tirzepatide. Identify the specific limit being applied and address, line by line, why your request is within or justified to exceed that limit.

## Criteria-Mapping Structure

For a quantity-limit appeal, structure your submission as: Aetna's stated limit | FDA-approved titration schedule reference | Your prescriber's clinical rationale | Chart documentation. If the prescribed quantity reflects an ongoing titration per the approved label, make that connection explicit — it is often the strongest single argument in a quantity-limit appeal.

Confirm the current quantity-limit parameters in Aetna's published drug policy and cross-reference the FDA prescribing information before submitting, as both are subject to periodic revision.